Alkermes/ALKS

$30.24

1.85%
-
1D1W1MYTD1YMAX

About Alkermes

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Ticker

ALKS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Pops

Employees

2,100

Headquarters

Dublin, Ireland

Alkermes Metrics

BasicAdvanced
$5.05B
Market cap
14.64
P/E ratio
$2.07
EPS
0.53
Beta
-
Dividend rate

What the Analysts think about Alkermes

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 10 analysts.
15.41% upside
High $43.00
Low $25.00
$30.24
Current price
$34.90
Average price target

Alkermes Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
29.86% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$377.4M
-0.92%
Net income
$112.7M
136.27%
Profit margin
29.86%
138.5%

Alkermes Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 57.15%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.01
$0.55
$0.64
$0.22
-
Expected
-$0.01
$0.46
$0.44
$0.51
$0.69
Surprise
-174.07%
19.05%
44.7%
-57.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Alkermes stock

Buy or sell Alkermes stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing